Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial

被引：1

作者：

de Souza, M. S. ^{[1
]}

Trichavaroj, R. ^{[1
]}

Schuetz, A. ^{[1
]}

Chuenarom, W. ^{[1
]}

Phuang-ngem, Y. ^{[1
]}

Jongrakthaitae, S. ^{[1
]}

Ratto-Kim, S. ^{[2
]}

Nitayaphan, S. ^{[1
]}

Dally, L. ^{[3
]}

Rerks-Ngam, S. ^{[4
]}

Tartaglia, J. ^{[5
]}

Francis, D. ^{[6
]}

Michael, N. L. ^{[2
]}

Paris, R. M. ^{[1
]}

Kim, J. H. ^{[2
]}

机构：

[1] US Mil HIV Res Program AFRIMS, Bangkok, Thailand

[2] US Mil HIV Res Program, Rockville, MD USA

[3] EMMES Corp, Rockville, MD USA

[4] Minist Publ Hlth, Nonthaburi, Thailand

[5] Sanofi Pasteur, Toronto, ON, Canada

[6] Global Solutat Infect Dis, San Francisco, CA USA

来源：

RETROVIROLOGY | 2009年 / 6卷

关键词：

Humoral Immune Response; Vaccine Candidate; Vaccine Trial; Recombinant Form; Vaccine Antigen;

D O I：

10.1186/1742-4690-6-S3-O52

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页数：1

共 50 条

[1] OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
MS de Souza
R Trichavaroj
A Schuetz
W Chuenarom
Y Phuang-ngem
S Jongrakthaitae
S Ratto-Kim
S Nitayaphan
L Dally
S Rerks-Ngam
J Tartaglia
D Francis
NL Michael
RM Paris
JH Kim
Retrovirology, 6
[2] Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144
Robb, Merlin L.
Rerks-Ngarm, Supachai
Nitayaphon, Sorachai
Pitisuttithum, Punnee
Kaewkungwal, Jaranit
Kunasol, Prayura
Khamboonruang, Chirasak
Thongcharoen, Prasert
Morgan, Patricia
Benenson, Michael
Paris, Robert M.
Chiu, Joseph
Adams, Elizabeth
Francis, Donald
Gurunathan, Sanjay
Tartaglia, Jim
Gilbert, Peter
Stablein, Don
Michael, Nelson L.
Kim, Jerome H.
LANCET INFECTIOUS DISEASES, 2012, 12 (07): : 531 - 537
[3] Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
Pitisuttithum, Punnee
Rerks-Ngarm, Supachai
Bussaratid, Valai
Dhitavat, Jittima
Maekanantawat, Wirach
Pungpak, Swangjai
Suntharasamai, Pravan
Vanijanonta, Sirivan
Nitayapan, Sorachai
Kaewkungwal, Jaranit
Benenson, Michael
Morgan, Patricia
O'Connell, Robert J.
Berenberg, Jeffrey
Gurunathan, Sanjay
Francis, Donald P.
Paris, Robert
Chiu, Joseph
Stablein, Donald
Michael, Nelson L.
Excler, Jean-Louis
Robb, Merlin L.
Kim, Jerome H.
PLOS ONE, 2011, 6 (12):
[4] Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial
Pitisuttithum, Punnee
Nitayaphan, Sorachai
Chariyalertsak, Suwat
Kaewkungwal, Jaranit
Dawson, Peter
Dhitavat, Jittima
Phonrat, Benjaluck
Akapirat, Siriwat
Karasavvas, Nicos
Wieczorek, Lindsay
Polonis, Victoria
Eller, Michael A.
Pegu, Poonam
Kim, Dohoon
Schuetz, Alexandra
Jongrakthaitae, Surat
Zhou, Yingjun
Sinangil, Faruk
Phogat, Sanjay
Diazgranados, Carlos A.
Tartaglia, James
Heger, Elizabeth
Smith, Kirsten
Michael, Nelson L.
Excler, Jean-Louis
Robb, Merlin L.
Kim, Jerome H.
O'Connell, Robert J.
Vasan, Sandhya
LANCET HIV, 2020, 7 (04): : E238 - E248
[5] NK Cell Changes after a Late Boost with ALVAC-HIV and AIDSVAX® B/E in HIV-Uninfected Thai Adults from RV144
Eller, Michael A.
Creegan, Matthew
Costanzo, Margaret C.
Rerks-Ngarm, Supachai
Pitisuttithum, Punnee
Schuetz, Alexandra
Sinangil, Faruk
Phogat, Sanjay
Robb, Merlin L.
Michael, Nelson L.
Excler, Jean-Louis
Kim, Jerome H.
O'Connell, Robert J.
Vasan, Sandhya
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 76 - 76
[6] Safety and Reactogenicity of ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Prime-Boost Vaccination Regimen in a Community-Based Efficacy Trial
Pitisuttithum, P.
Rerks-Ngarm, S.
Bussaratid, V.
Dhitavat, J.
Maekanantawat, W.
Pungpak, S.
Suntharasamai, P.
Vanijanonta, S.
Nitayapan, S.
Kaewkungwal, J.
Chunsuttiwat, S.
Premsri, N.
Benenson, M.
Morgan, P.
Berenberg, J.
Gurunathan, S.
Francis, D. P.
Chiu, J.
Excler, J.
Robb, M. L.
Stablein, D.
Michael, N. L.
Kim, J.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A74 - A74
[7] Vaccine Induced Seroreactivity in RV144 Vaccine Recipients in RV305, a Placebo Controlled Assessment of Late Boosts with ALVAC-HIV and AIDSVAX B/E
Eamsila, Chirapa
Akapirat, Siriwat
Nitayapan, Sorachai
Rerks-Ngarm, Supachai
Pitisutthithum, Punnee
Vasan, Sandhya
Excler, Jean-Louis
Karasavvas, Nicos
Ngauy, Viseth
Robb, Merlin L.
Michael, Nelson L.
Kim, Jerome H.
O'Connell, Robert J.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A191 - A191
[8] The RV144 Thai HIV vaccine trial
Plotkin, Stanley A.
HUMAN VACCINES, 2010, 6 (02): : 159 - 159
[9] Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1-Infected Women in Uganda (HPTN 027): The First Pediatric HIV Vaccine Trial in Africa
Kaleebu, Pontiano
Njai, Harr Freeya
Wang, Lei
Jones, Norman
Ssewanyana, Isaac
Richardson, Paul
Kintu, Kenneth
Emel, Lynda
Musoke, Philippa
Fowler, Mary Glenn
Ou, San-San
Jackson, J. Brooks
Guay, Laura
Andrew, Philip
Baglyos, Lynn
Cao, Huyen
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : 268 - 277
[10] HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX® B/E
Paris, Robert
Bejrachandra, Sasitorn
Thongcharoen, Prasert
Nitayaphan, Sorachai
Pitisuttithum, Punnee
Sambor, Anna
Gurunathan, Sanjay
Francis, Donald
Ratto-Kim, Silvia
Karnasuta, Chitraporn
de Souza, Mark S.
Polonis, Victoria R.
Brown, Arthur E.
Kim, Jerome H.
Stephens, Henry A.
VACCINE, 2012, 30 (05) : 832 - 836

← 1 2 3 4 5 →